GlassScriptPhysician profile
Alivia M Tekoppel
NPI 1568897452
$1,126.16
in general payments reported to CMS, 2019-2025
23 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2022: $220 · 2023: $189 · 2024: $130 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $150.19 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $132.23 | 2021-2025 | |
| Novo Nordisk INC | $125.22 | 2021-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $83.37 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $82.77 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $73.68 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $63.88 | 2021-2025 | Airsupra |
| Janssen Pharmaceuticals, INC | $61.60 | 2022 | |
| Amgen INC. | $52.27 | 2021-2022 | |
| Lilly USA, LLC | $44.93 | 2022-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.68 | 2021-2024 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $28.91 | 2025 | |
| Horizon Therapeutics Plc | $24.43 | 2021 | |
| Mylan Specialty L.P. | $23.22 | 2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $23.15 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.99 | 2025 | Caplyta |
| Pfizer INC. | $19.59 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.99 | 2023 | Seglentis |
| Eisai INC. | $15.20 | 2021 | |
| Esperion Therapeutics, INC. | $14.79 | 2024 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $14.32 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.14 | 2021 | |
| Phathom Pharmaceuticals, INC. | $11.61 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alivia Tekoppel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.